Key Takeaways
Cellino's Nebula technology reduces iPSC manufacturing costs by at least 10 times.
Automated cell growth and laser technology enable mass production of personalized treatments.
$25 million ARPA-H grant and $96 million in venture capital funding support Cellino's development.
Expert endorsement highlights Cellino's innovative approach and multidisciplinary team.
Cellino aims to make personalized iPSCs widely available, transforming disease treatment.